Tirosin Kinase Inhibitors in Chronic Graft versus Host Disease: From Bench to Bedside

<table>Antifibrotic effect of TKI: the original target of Imatinib, c-Abl, is involved in several molecular pathways leading to fibrogenesis. Interference of TKI with other molecules involved in fibrotic pathways (PDGFR and Src kinases) are not illustrated due to required simplification.</table>

The Scientific World Journal

fig3

Figure 3

Figure 3: Tirosin Kinase Inhibitors in Chronic Graft versus Host Disease: From Bench to Bedside 